Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
NCT01679080 · University of Aarhus · PHASE2 · terminated · last registry update 2021-06-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Eli Lilly has withdrawn support to the study of teriparatide and placebo pens. The study was not able to continue as a randomized study without the supply of placebo pens.” | – | Registry record, University of Aarhus |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FDPS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-27Also stopped (terminated): University of Leeds, zoledronic acid (NCT00458796)
- 2022-05-26Also stopped (terminated): University College Dublin, Alendronate + Placebo (NCT02322099)
- 2022-03-31Phase 3 first posted: Shandong New Time Pharmaceutical Co., LTD, Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo (NCT05305183)
- 2022-03-02Results posted on the registry: Ultragenyx Pharmaceutical Inc, setrusumab + zoledronic acid (optional) (NCT03118570)
- 2022-02-25Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib + Zoledronic Acid (NCT00566618)
- 2022-02-23Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Acide Zoledronique (NCT02739555)
- 2021-12-21Phase 3 first posted: Assiut University, Zoledronic Acid 4 MG (NCT05164952)
- 2021-11-08Also stopped (terminated): Institut Bergonié, Glivec (NCT00210119)
- 2021-11-03Phase 3 first posted: Shenzhen People's Hospital, Denosumab + Zoledronic acid (NCT05106517)
- 2021-10-28Results posted on the registry: Institut Bergonié, Glivec (NCT00210119)
- 2021-10-22Also stopped (terminated): Centre Leon Berard, denosumab (NCT03408652)
- 2021-10-18Results posted on the registry: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 99Tc-MDP + Fosamax (NCT02304757)
- 2021-09-29Results posted on the registry: Mahidol University, Generic alendronate (NCT02371252)
- 2021-06-22Also stopped (terminated): First Affiliated Hospital, Sun Yat-Sen University, Zoledronate (NCT01623908)
- 2021-06-10Phase 3 first posted: Wake Forest University Health Sciences, Risedronate + Placebo (NCT04922333)
- 2021-06-02Results posted on the registry: Northwestern University, Zoledronic acid + Placebo (NCT02325414)
- 2021-05-26Results posted on the registry: Novartis Pharmaceuticals, zoledronic acid (NCT00622505)
- 2021-05-26Results posted on the registry: Novartis Pharmaceuticals, Zoledronic Acid (NCT00740129)
- 2021-04-29Results posted on the registry: Massachusetts General Hospital, Zoledronic Acid (NCT03424239)
- 2021-04-14Results posted on the registry: Karolinska Institutet, Risedronate (NCT01950169)
- 2021-03-03Phase 3 first posted: Karen Klahr Miller, MD, Romosozumab Prefilled Syringe + Placebo (NCT04779216)
- 2021-01-22Results posted on the registry: Massachusetts General Hospital, denosumab + teriparatide (NCT02176382)
- 2021-01-22Results posted on the registry: Wake Forest University Health Sciences, Risedronate Sodium 150 MG (NCT03411902)
- 2021-01-14Results posted on the registry: Aarhus University Hospital, Zoledronic Acid (NCT03087851)
- 2021-01-12Phase 3 first posted: Sherief Abd-Elsalam, nonselective beta blocker + cardio-selective beta blocker group (NCT04704947)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision